These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38090966)

  • 1. Pneumothorax in lung metastasis of advanced soft tissue sarcoma patients treated with oral pazopanib.
    Sarkar S; Mishra PK; Mukhopadhyay S; Sen S; Biswas B
    Indian J Cancer; 2024 Apr; 61(2):278-281. PubMed ID: 38090966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis.
    Aiba H; Kimura H; Yamada S; Okamoto H; Hayashi K; Miwa S; Kawaguchi Y; Saito S; Sakai T; Tatematsu T; Nakanishi R; Murakami H
    PLoS One; 2021; 16(7):e0254866. PubMed ID: 34270626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of bilateral spontaneous pneumothorax during pazopanib therapy for pulmonary soft tissue sarcoma metastases. What to do when there is so few evidence?].
    Agrafiotis AC; Prieto M; Verhaeghe JL; Siat J; Grosdidier G; Rios M
    Rev Pneumol Clin; 2016 Oct; 72(5):293-295. PubMed ID: 27561973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
    Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
    Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathological response in children and adults with large unresected intermediate-grade or high-grade soft tissue sarcoma receiving preoperative chemoradiotherapy with or without pazopanib (ARST1321): a multicentre, randomised, open-label, phase 2 trial.
    Weiss AR; Chen YL; Scharschmidt TJ; Chi YY; Tian J; Black JO; Davis JL; Fanburg-Smith JC; Zambrano E; Anderson J; Arens R; Binitie O; Choy E; Davis JW; Hayes-Jordan A; Kao SC; Kayton ML; Kessel S; Lim R; Meyer WH; Million L; Okuno SH; Ostrenga A; Parisi MT; Pryma DA; Randall RL; Rosen MA; Schlapkohl M; Shulkin BL; Smith EA; Sorger JI; Terezakis S; Hawkins DS; Spunt SL; Wang D
    Lancet Oncol; 2020 Aug; 21(8):1110-1122. PubMed ID: 32702309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary spontaneous pneumothorax in patients with sarcoma treated with Pazopanib, a case control study.
    Sabath B; Muhammad HA; Balagani A; Ost DE; Vakil E; Ahmed T; Vial MR; Grosu HB
    BMC Cancer; 2018 Oct; 18(1):937. PubMed ID: 30285733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of pazopanib as a second-line treatment and beyond for soft tissue sarcomas: A real-life tertiary-center experience in the MENA region.
    Halim NA; Sayed RE; Alameh IA; Khoury J; Nakib CE; Zerdan MB; Charafeddine M; Farhat F; Karak FE; Assi HI
    Cancer Treat Res Commun; 2021; 26():100275. PubMed ID: 33340905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II trial comparing pazopanib with doxorubicin as first-line treatment in elderly patients with metastatic or advanced soft tissue sarcoma (EPAZ): study protocol for a randomized controlled trial.
    Karch A; Koch A; Grünwald V
    Trials; 2016 Jul; 17(1):312. PubMed ID: 27387325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pneumothorax during Pazopanib Therapy in a Patient with Soft Tissue Sarcoma].
    Kanno N; Nakahashi K; Shiikawa M; Endo M; Numahata K; Shiono S
    Gan To Kagaku Ryoho; 2021 Jul; 48(7):975-977. PubMed ID: 34267040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of Predictive Biomarkers of the Response to Pazopanib Based on an Integrative Analysis of High-grade Soft-tissue Sarcomas: Analysis of a Tumor Sample from a Responder and Patients with Other Soft-tissue Sarcomas.
    Suehara Y; Kohsaka S; Yamaguchi S; Hayashi T; Kurihara T; Sano K; Sasa K; Akaike K; Ueno T; Kojima S; Ikegami M; Mizuno S; Okubo T; Kim Y; Kaneko K; Saito T; Kato S; Mano H
    Clin Orthop Relat Res; 2020 Nov; 478(11):2461-2476. PubMed ID: 32567826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses.
    Cesne AL; Bauer S; Demetri GD; Han G; Dezzani L; Ahmad Q; Blay JY; Judson I; Schöffski P; Aglietta M; Hohenberger P; Gelderblom H
    BMC Cancer; 2019 Aug; 19(1):794. PubMed ID: 31409302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072.
    Kasper B; Sleijfer S; Litière S; Marreaud S; Verweij J; Hodge RA; Bauer S; Kerst JM; van der Graaf WTA
    Ann Oncol; 2014 Mar; 25(3):719-724. PubMed ID: 24504442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment.
    Nakano K; Inagaki L; Tomomatsu J; Motoi N; Gokita T; Ae K; Tanizawa T; Shimoji T; Matsumoto S; Takahashi S
    Clin Oncol (R Coll Radiol); 2014 Jun; 26(6):357. PubMed ID: 24630810
    [No Abstract]   [Full Text] [Related]  

  • 14. Pazopanib-induced fatal heart failure in a patient with unresectable soft tissue sarcoma and review of literature.
    Karaağaç M; Eryılmaz MK
    J Oncol Pharm Pract; 2020 Apr; 26(3):768-774. PubMed ID: 31547750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study.
    Oh CR; Hong JY; Kim JH; Lee JS; Kim HS; Kim TW; Ahn JH; Kim JE
    Target Oncol; 2020 Aug; 15(4):485-493. PubMed ID: 32607656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas.
    Schulte B; Mohindra N; Milhem M; Attia S; Robinson S; Monga V; Hirbe AC; Oppelt P; Charlson J; Helenowski I; Abbinanti S; Cehic R; Okuno S; Van Tine BA; Agulnik M
    Br J Cancer; 2021 Aug; 125(4):528-533. PubMed ID: 34050255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hand-foot skin reaction predicts treatment outcome of pazopanib in patients with metastatic soft tissue sarcoma: A multicenter study in the Asian population.
    Huang PW; Chou WC; Shen WC; Hung CY; Huang KG; Su YL; Lu CH; Liu CT; Chang YS; Liau CT
    Asia Pac J Clin Oncol; 2018 Aug; 14(4):353-360. PubMed ID: 29900662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How we use pazopanib in treating soft-tissue sarcoma: experience at our multidisciplinary sarcoma centers.
    Van Tine BA; Trent JC
    Curr Med Res Opin; 2019 Apr; 35(4):623-629. PubMed ID: 30652922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma.
    Subbiah V; Meyer C; Zinner R; Meric-Bernstam F; Zahurak ML; O'Connor A; Roszik J; Shaw K; Ludwig JA; Kurzrock R; Azad NA
    Clin Cancer Res; 2017 Aug; 23(15):4027-4034. PubMed ID: 28377484
    [No Abstract]   [Full Text] [Related]  

  • 20. Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma.
    Kim JH; Park HS; Heo SJ; Kim SK; Han JW; Shin KH; Kim SH; Hur H; Kim KS; Choi YD; Kim S; Lee YH; Suh JS; Ahn JB; Chung HC; Noh SH; Rha SY; Kim HS
    Oncology; 2019; 96(2):59-69. PubMed ID: 30336470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.